NCT07392528

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA（QT-019C） in Patients With Relapsed / Refractory Neurological Autoimmune Diseases

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Tianjin Huanhu Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open label, single-site, dose-escalation study in up to 15 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells（QT-019C）.

Detailed description

This is an investigator-initiated trial to evaluate the safety and efficacy of universal CD19/BCMA CAR T-cells（QT-019C） in Relapsed or Refractory Neurological Autoimmune Diseases.Study intervention consists of a single infusion of universal CAR T-cells administered intravenously after a lymphodepleting therapy regimen of cyclophosphamide.Interim analysis will be performed when participants finish the visit 90 days after CAR T-cell infusion.

Conditions

• Neuromyelitis Optica Spectrum Disorders
• Multiple Sclerosis
• Myasthenia Gravis

Interventions

Type	Name	Description
DRUG	QT-019C	Universal allogeneic anti-CD19/BCMA CAR T-cells

Timeline

• Start date: 2026-03-01
• Primary completion: 2027-06-01
• Completion: 2028-12-01
• First posted: 2026-02-06
• Last updated: 2026-02-11

Locations

1 site across 1 country: China